Summary
Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript
Lifecore Biomedical, Inc. ( LFCR ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Josephs - President, CEO & Director Ryan Lake - Executive VP & CFO Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Hannah Hefley - Stephens Inc., Research Division Lucas Baranowski - KeyBanc Capital Markets Inc., Research Division Christine Rains - William Blair & Company L.L.C., Research Division Presentation Stephanie Diaz Vida Strategic Partners, Inc. Good afternoon, and thank you for joining us today to discuss Lifecore Biomedical's Third Quarter 2025 Earnings results for the 3 months ended September 30, 2025.
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
Universal Electronics Inc. (UEIC) Q4 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Paul Josephs - President, CEO & Director Ryan D. Lake - EVP & CFO Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Maxwell Andrew Smock - William Blair & Company L.L.C.
Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript
Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q3 2025 Earnings Conference Call April 3, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, IR Paul Josephs - CEO Ryan Lake - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Michael Petusky - Barrington Research Operator Good afternoon, and thank you for joining Lifecore's Fiscal 2025 Third Quarter Earnings Call. During the call, all participants will be in a listen-only mode.
Lifecore Biomedical, Inc. (LFCR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Lifecore Biomedical, Inc. ever had a stock split?
Lifecore Biomedical, Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Paul Josephs CEO | NASDAQ (NGS) Exchange | US5147661046 ISIN |
| US Country | 524 Employees | - Last Dividend | - Last Split | 15 Feb 1996 IPO Date |
Overview
Lifecore Biomedical, Inc., together with its subsidiaries, is renowned for being an integrated contract development and manufacturing organization with a broad international and domestic reach. Previously known as Landec Corporation until its rebranding in November 2022, Lifecore Biomedical has carved a niche for itself in the pharmaceutical industry since its inception in 1965. Based in Chaska, Minnesota, this organization has established itself as a crucial player in the production of pharmaceutical-grade sodium hyaluronate (HA), catering to a variety of medical conditions and procedures throughout the United States and beyond.
Products and Services
Lifecore Biomedical, Inc. offers an extensive array of products and services designed to meet the diverse needs of the healthcare industry, focusing particularly on sodium hyaluronate (HA) based solutions:
- Pharmaceutical-grade Sodium Hyaluronate (HA) in Bulk Form: The cornerstone of Lifecore Biomedical's product line, this high-quality HA is produced for various medical applications, reflecting the company's expertise in biochemical manufacturing.
- Formulated and Filled Syringes and Vials: Lifecore Biomedical specializes in the formulation and aseptic filling of syringes and vials for injectable products. These sterilized products are meticulously prepared for treating various medical conditions, ensuring safety and efficacy for end-users.
- Technology Development Services: Partners of Lifecore Biomedical have access to cutting-edge technology development services, facilitating the innovation of HA-based and non-HA based products tailored to specific medical needs.
- Material Component Changes: This service underscores Lifecore's capability to adapt to the evolving requirements of pharmaceutical products by offering versatile solutions in material component adjustments.
- Analytical Method Development: Leveraging advanced analytical techniques, Lifecore Biomedical provides comprehensive method development services to ensure the quality and consistency of pharmaceutical products.
- Formulation Development: Custom formulation development services are available, making it possible for partners to create specific product compositions that meet unique therapeutic needs.
- Pilot Studies: Lifecore facilitates pilot studies to test the feasibility and effectiveness of new pharmaceutical formulations and products in a controlled environment before full-scale production.
- Stability Studies: The company conducts stability studies to ensure that products maintain their integrity, potency, and efficacy throughout their shelf life.
- Process Validation: Lifecore Biomedical offers process validation services, confirming that pharmaceutical manufacturing processes consistently produce outcomes meeting predetermined specifications and quality attributes.
- Production of Materials for Clinical Studies: Lifecore provides manufacturing services for the production of materials intended for use in clinical studies, an essential step in the development and approval process of new pharmaceutical products.
Contact Information
